Clinical Trial Update: A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) [Phase 2]

View source ↗

Summary

Phase 2 study MK-6024-017 evaluating efinopegdutide in compensated cirrhosis due to nonalcoholic fatty liver disease and nonalcoholic steatohepatitis; the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Efinopegdutide (efinopegdutide)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | Status: ACTIVE_NOT_RECRUITING